These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 2457036

  • 1. A common neoepitope is created when the reactive center of C1-inhibitor is cleaved by plasma kallikrein, activated factor XII fragment, C1 esterase, or neutrophil elastase.
    de Agostini A, Patston PA, Marottoli V, Carrel S, Harpel PC, Schapira M.
    J Clin Invest; 1988 Aug; 82(2):700-5. PubMed ID: 2457036
    [Abstract] [Full Text] [Related]

  • 2. Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils.
    Eldering E, Huijbregts CC, Nuijens JH, Verhoeven AJ, Hack CE.
    J Clin Invest; 1993 Mar; 91(3):1035-43. PubMed ID: 8450033
    [Abstract] [Full Text] [Related]

  • 3. Expression of functional human C1 inhibitor in COS cells.
    Eldering E, Nuijens JH, Hack CE.
    J Biol Chem; 1988 Aug 25; 263(24):11776-9. PubMed ID: 2841334
    [Abstract] [Full Text] [Related]

  • 4. Substrate properties of C1 inhibitor Ma (alanine 434----glutamic acid). Genetic and structural evidence suggesting that the P12-region contains critical determinants of serine protease inhibitor/substrate status.
    Skriver K, Wikoff WR, Patston PA, Tausk F, Schapira M, Kaplan AP, Bock SC.
    J Biol Chem; 1991 May 15; 266(14):9216-21. PubMed ID: 2026621
    [Abstract] [Full Text] [Related]

  • 5. C1 inhibitor: analysis of the role of amino acid residues within the reactive center loop in target protease recognition.
    Zahedi R, MacFarlane RC, Wisnieski JJ, Davis AE.
    J Immunol; 2001 Aug 01; 167(3):1500-6. PubMed ID: 11466370
    [Abstract] [Full Text] [Related]

  • 6. Effect of cleavage of the heavy chain of human plasma kallikrein on its functional properties.
    Colman RW, Wachtfogel YT, Kucich U, Weinbaum G, Hahn S, Pixley RA, Scott CF, de Agostini A, Burger D, Schapira M.
    Blood; 1985 Feb 01; 65(2):311-8. PubMed ID: 3871342
    [Abstract] [Full Text] [Related]

  • 7. Proteolytic cleavage and inactivation of alpha 2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase.
    Brower MS, Harpel PC.
    J Biol Chem; 1982 Aug 25; 257(16):9849-54. PubMed ID: 6980881
    [Abstract] [Full Text] [Related]

  • 8. Primary structure of the reactive site of human C1-inhibitor.
    Salvesen GS, Catanese JJ, Kress LF, Travis J.
    J Biol Chem; 1985 Feb 25; 260(4):2432-6. PubMed ID: 3919001
    [Abstract] [Full Text] [Related]

  • 9. Prekallikrein activation and kallikrein inactivation in human plasma.
    van der Graaf F, Keus JF, Koedam JA, Rietveld A, Bouma BN.
    Adv Exp Med Biol; 1983 Feb 25; 156():143-8. PubMed ID: 6190365
    [No Abstract] [Full Text] [Related]

  • 10. Structural and functional characterization of factor XII.
    Tans G, Rosing J.
    Semin Thromb Hemost; 1987 Jan 25; 13(1):1-14. PubMed ID: 3551074
    [Abstract] [Full Text] [Related]

  • 11. C1-inhibitor polymers activate the FXII-dependent kallikrein-kinin system: Implication for a role in hereditary angioedema.
    Madsen DE, Sidelmann JJ, Biltoft D, Gram J, Hansen S.
    Biochim Biophys Acta; 2015 Jun 25; 1850(6):1336-42. PubMed ID: 25800206
    [Abstract] [Full Text] [Related]

  • 12. The structural basis for neutrophil inactivation of C1 inhibitor.
    Pemberton PA, Harrison RA, Lachmann PJ, Carrell RW.
    Biochem J; 1989 Feb 15; 258(1):193-8. PubMed ID: 2930506
    [Abstract] [Full Text] [Related]

  • 13. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway.
    Kaplan AP, Joseph K.
    Adv Immunol; 2014 Feb 15; 121():41-89. PubMed ID: 24388213
    [Abstract] [Full Text] [Related]

  • 14. Mechanism of serpin action: evidence that C1 inhibitor functions as a suicide substrate.
    Patston PA, Gettins P, Beechem J, Schapira M.
    Biochemistry; 1991 Sep 10; 30(36):8876-82. PubMed ID: 1888745
    [Abstract] [Full Text] [Related]

  • 15. alpha(1)-Proteinase inhibitor mutants with specificity for plasma kallikrein and C1s but not C1.
    Sulikowski T, Bauer BA, Patston PA.
    Protein Sci; 2002 Sep 10; 11(9):2230-6. PubMed ID: 12192078
    [Abstract] [Full Text] [Related]

  • 16. Protection by recombinant alpha 1-antitrypsin Ala357 Arg358 against arterial hypotension induced by factor XII fragment.
    Schapira M, Ramus MA, Waeber B, Brunner HR, Jallat S, Carvallo D, Roitsch C, Courtney M.
    J Clin Invest; 1987 Aug 10; 80(2):582-5. PubMed ID: 3497179
    [Abstract] [Full Text] [Related]

  • 17. Human plasma kallikrein releases neutrophil elastase during blood coagulation.
    Wachtfogel YT, Kucich U, James HL, Scott CF, Schapira M, Zimmerman M, Cohen AB, Colman RW.
    J Clin Invest; 1983 Nov 10; 72(5):1672-7. PubMed ID: 6556194
    [Abstract] [Full Text] [Related]

  • 18. Interactions of plasma kallikrein and C1-s with normal and dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema: analytic gel studies.
    Donaldson VH, Wagner CJ, Tsuei B, Kindness G, Bing DH, Harrison RA, Rosen FS.
    Blood; 1987 Apr 10; 69(4):1096-101. PubMed ID: 3493816
    [Abstract] [Full Text] [Related]

  • 19. The plasma bradykinin-forming pathways and its interrelationships with complement.
    Kaplan AP, Ghebrehiwet B.
    Mol Immunol; 2010 Aug 10; 47(13):2161-9. PubMed ID: 20580091
    [Abstract] [Full Text] [Related]

  • 20. Enzymatic inactivation of human plasma C1-inhibitor and alpha 1-antichymotrypsin by Pseudomonas aeruginosa proteinase and elastase.
    Catanese J, Kress LF.
    Biochim Biophys Acta; 1984 Aug 28; 789(1):37-43. PubMed ID: 6432051
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.